GLP-1 Weight-Loss/Diabetes Industries Continue Transition to Oral Medications
Key Highlights
- ➤GLP-1 market valued at $73.4 billion in 2026, projected $254.2 billion by 2034
- ➤71% of respondents prefer daily GLP-1 pills over weekly injections
- ➤Oral semaglutide captures about 35% of new prescriptions
- ➤Novo CEO Mike Doustdar says oral medications could capture half the global market
- ➤Lexaria evaluates DehydraTECH for oral GLP-1 absorption and side-effect reduction
Expert Statements
Ludovic Helfgott, Executive Vice President of Novo
“could actually represent up to a third-plus of that market overall.”
Mike Doustdar, CEO of Novo
“oral medications could capture as much as half of the global market.”
Richard Christopher, CEO of Lexaria Bioscience Corp.
“For roughly 3 years, Lexaria has been demonstrating the applicability of our DehydraTECH drug delivery technology to the oral GLP-1 market - a segment that barely existed when we began those efforts,”
Richard Christopher, CEO of Lexaria Bioscience Corp.
“Our corporate vision is sound and in harmony with market needs. We are working diligently towards DehydraTECH's eventual adoption within this large and rapidly growing marketplace.”
KELOWNA, BC / ACCESS Newswire / October 6, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is providing this strategic update.
Lexaria's DehydraTECH™ technology is currently being evaluated both by Lexaria and pharmaceutical industry partners for use within the rapidly growing GLP-1 receptor agonist and weight-loss/diabetes drug industries. Those industry segments were valued at $62.8 billion in 2025 and are estimated to grow to $73.4 billion in 2026 and to $254.2 billion by 2034. This growth far exceeds earlier forecasts and validates Lexaria's 2023 strategic decision to increasingly focus its resources towards this sector.
Get started
Create a free account to read the full story.